TP 53 status and estrogen receptor-beta in triple negative breast cancer management in Africa: Time to rethink regime management of triple negative breast cancer and save more lives in Nigeria.
作者信息
Nzegwu Martin Arinzechukwu, Nwokoro Onyekachi, Nnamani Christian, Enemuo Vincent C, Nzegwu Victor Ifeanyichukwu, Nwoye Ogochukwu, Edeh Anthony, Nwankwo Kenneth
机构信息
Department of Morbid Anatomy, University of Nigeria, Nsukka, Nigeria.
Department of Surgery, University of Nigeria, Nsukka, Nigeria.
出版信息
Rare Tumors. 2021 Oct 7;13:20363613211050355. doi: 10.1177/20363613211050355. eCollection 2021.
Abstract
摘要
相似文献
1
TP 53 status and estrogen receptor-beta in triple negative breast cancer management in Africa: Time to rethink regime management of triple negative breast cancer and save more lives in Nigeria.
Rare Tumors. 2021 Oct 7;13:20363613211050355. doi: 10.1177/20363613211050355. eCollection 2021.
2
Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer.
Exp Ther Med. 2015 Jun;9(6):2147-2150. doi: 10.3892/etm.2015.2380. Epub 2015 Mar 23.
3
Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
BMC Cancer. 2016 Dec 21;16(1):951. doi: 10.1186/s12885-016-2973-y.
4
Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Jpn J Clin Oncol. 2012 May;42(5):375-86. doi: 10.1093/jjco/hys034. Epub 2012 Mar 26.
5
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.
6
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Zhonghua Zhong Liu Za Zhi. 2012 Jun;34(6):465-8. doi: 10. 3760/cma.j.issn.0253-3766.2012.06.014.
7
Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast.
Asian Pac J Cancer Prev. 2016;17(8):3911-6.
8
Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Hum Pathol. 2017 Apr;62:23-32. doi: 10.1016/j.humpath.2016.10.006. Epub 2016 Nov 2.
9
Expression and clinical significance of androgen receptor in triple negative breast cancer.
Chin J Cancer. 2010 Jun;29(6):585-90. doi: 10.5732/cjc.009.10673.
10
Triple-negative breast cancer: an unmet medical need.
Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01.
引用本文的文献
1
Comparative Molecular Docking of Apigenin and Luteolin versus Conventional Ligands for TP-53, pRb, APOBEC3H, and HPV-16 E6: Potential Clinical Applications in Preventing Gynecological Malignancies.
Curr Issues Mol Biol. 2024 Oct 3;46(10):11136-11155. doi: 10.3390/cimb46100661.
本文引用的文献
1
Predictive and prognostic relevance of immunohistochemical testing of estrogen and progesterone receptors in breast cancer in South East Nigeria: A review of 417 cases.
Rare Tumors. 2021 Apr 29;13:20363613211006338. doi: 10.1177/20363613211006338. eCollection 2021.
2
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
J Natl Cancer Inst. 2019 Nov 1;111(11):1202-1215. doi: 10.1093/jnci/djz051.
3
TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters.
J Natl Cancer Inst. 2019 Nov 1;111(11):1118-1119. doi: 10.1093/jnci/djz052.
4
Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives.
J Glob Oncol. 2018 Jul;4:1-20. doi: 10.1200/JGO.17.00116.
5
Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).
Ann Oncol. 2013 Aug;24(8):1986-93. doi: 10.1093/annonc/mdt132. Epub 2013 Apr 11.
6
A bi-faceted role of estrogen receptor β in breast cancer.
Endocr Relat Cancer. 2013 May 30;20(3):R127-39. doi: 10.1530/ERC-12-0389. Print 2013 Jun.
7
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results.
Indian J Med Paediatr Oncol. 2010 Jul;31(3):76-8. doi: 10.4103/0971-5851.73588.
8
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Cancer J. 2010 Jan-Feb;16(1):48-52. doi: 10.1097/PPO.0b013e3181cf01eb.
9
Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Mod Pathol. 2010 Feb;23(2):197-204. doi: 10.1038/modpathol.2009.158. Epub 2009 Nov 6.
10
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
J Clin Oncol. 2008 Aug 1;26(22):3727-34. doi: 10.1200/JCO.2007.14.2968.
Zotero 插件